Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ResMed

ResMed Stock: Analyst Estimates & Ratings

Despite ResMed’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Weight-loss drugs not lights out for ResMed: CEO

Sleep apnoea device manufacturer ResMed has continued to see revenue and net income grow, despite short-sellers claiming weight loss drugs threaten its market.

AAP

Five Stocks With Solid Growth History and a Promising Outlook

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again

ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.

Investors Business Daily

After Blowout Earnings, This Dividend Stock Still Looks Cheap

Despite its remarkable post-earnings rally, here's a dividend stock that still carries a bargain tag.

Barchart

Surging Alphabet Stock Leads Broad-Based Tech Rally; Nvidia Makes Bullish Move

The Nasdaq composite rallied sharply in the stock market today, helped by strong earnings reports from Microsoft and Google-parent Alphabet.

Investors Business Daily

How 'Megatrends' Like Weight-Loss Drugs And Smartwatches Are Bolstering ResMed

ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

Investors Business Daily

ResMed Surges And Retakes A Key Line As The Battle With Weight-Loss Drugs Rages

ResMed reported a strong December-quarter beat, an analyst said Thursday as RMD stock surged, retaking its 200-day moving average.

Investors Business Daily

FDA deems ResMed's respiratory device recall as most severe

Learn about the recent recall of ResMed's respiratory devices by the US FDA, deemed as the most serious. Find out more about the implications and what acti...

Top News

Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge

Sleep-apnea device maker ResMed broke out after earnings, continuing its accelerating growth pace.

Investors Business Daily

Australians losing sleep over cost of living crisis

Australians should take sleep seriously as a survey marking World Sleep Day sheds light on the impact of financial pressures, experts say.

AAP

ResMed rings up record $1B in sales in latest quarter led by connected sleep apnea devices

For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of the pandemic.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022

Upgrades

Benzinga

Here's How Much You Would Have Made Owning ResMed Stock In The Last 20 Years

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.66% on an annualized basis producing an average annual return of 18.75%. Currently, ResMed has a market capitalization of $30.88 billion.

Benzinga

Analyzing ResMed's Short Interest

ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all regular shares that are available for trading.

Benzinga

Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years

ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How

ResMed Inc (NYSE:RMD) has agreed to acquire privately-held MEDIFOX DAN, a Germany-based provider of out-of-hospital software solutions, from Hg, a software and services investor. MEDIFOX DAN's clinical, financial, and operational solutions are similar to ResMed's U.S. SaaS brands, MatrixCare and Brightree. MEDIFOX DAN's German customer base is complementary to the customers of ResMed's U.S.-based…

Benzinga

Analyst Ratings for ResMed

Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Upgrades

Benzinga

If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today

ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of $30.35 billion.

Benzinga

ResMed Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.

Benzinga

What 3 Analyst Ratings Have To Say About ResMed

Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract

ResMed Inc's (NYSE:RMD) Q3 FY22 sales increased by 12% Y/Y (+14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million. The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE:PHG) products. ResMed…

1 2 3

People

Samik Chatterjee

60 stories

Margaret Kaczor Andrew

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.